LDN 8mg for Weight Loss: Benefits, Risks, and Results

Dr. Shweta Patel, MD, FACOG

Board-certified OB/GYN • U.S. Navy veteran (13 years) • Author, The Book of Hormones • Founder, Gaya Wellness

Published July 30, 2025 • Updated May 3, 2026

LDN 8mg is being talked about as a quiet weight-loss tool: not as intense as a GLP-1, not as formal as an obesity medication, and supposedly helpful for inflammation, cravings, pain, and metabolism. I understand why that sounds attractive. Many women who come to Gaya have already tried strict dieting, supplements, detoxes, and willpower-based plans. They are tired of being told to work harder when the problem may be hormonal, inflammatory, metabolic, or medication-related.

But LDN deserves a more careful conversation than the internet usually gives it. Low-dose naltrexone may be useful for selected patients, especially when the target is pain, immune symptoms, or another off-label indication. That is different from saying LDN 8mg is a proven weight-loss medication. Benefits, risks, and results have to be separated. If we blur them together, women lose time and trust.

My position is not anti-LDN. My position is anti-overclaiming. If a woman has chronic pain, autoimmune symptoms, post-viral symptoms, sleep disruption, or medication limitations, LDN may be part of a thoughtful medical conversation. If the primary problem is obesity, insulin resistance, food noise, rapid abdominal weight gain, or repeated regain after appropriate lifestyle work, LDN alone is usually an underpowered answer.

What LDN 8mg Is and Is Not

Naltrexone is an opioid receptor antagonist. At standard doses, it is used for alcohol use disorder and opioid use disorder. At lower compounded doses, it is often called low-dose naltrexone, or LDN. Many traditional LDN protocols use doses around 1.5mg to 4.5mg, though some clinicians use higher off-label doses. An 8mg dose is still far below a common 50mg naltrexone tablet, but it is not automatically gentle, risk-free, or metabolically powerful.

The number 8mg creates confusion because each Contrave tablet contains naltrexone 8mg and bupropion 90mg in an extended-release combination. The current DailyMed prescribing information for Contrave describes it as an adjunct to reduced-calorie diet and increased physical activity for chronic weight management in appropriate adults. That is not the same thing as taking compounded naltrexone alone at bedtime.

This distinction matters clinically. Contrave combines an opioid antagonist with bupropion, an aminoketone antidepressant that affects appetite pathways and carries its own contraindications and monitoring requirements. LDN 8mg alone does not include bupropion. If a person uses Contrave data to promise LDN-alone results, they are borrowing evidence from a different medication.

Possible Benefits: Where LDN Might Fit

The most reasonable argument for LDN and weight is indirect. If a woman has pain that limits movement, sleep disruption from chronic symptoms, inflammatory flares that derail consistency, or cravings tied to alcohol or reward pathways, improving those barriers may support a better weight plan. In that situation, LDN is not melting fat. It may be helping a patient participate in the plan.

That distinction is not semantics. A tool that reduces one barrier can be valuable without being the central treatment. For example, if knee pain improves enough for walking and resistance training to become realistic, weight may improve. If sleep improves, appetite regulation may improve. If alcohol cravings decrease, calories and glucose swings may change. Those are real pathways, but they do not prove LDN is a primary obesity therapy.

The 2025 PubMed-indexed scoping review on low-dose naltrexone describes LDN as an emerging off-label treatment area across painful and other medical conditions. That supports continued study. It does not establish LDN 8mg as a reliable medication for fat loss, visceral fat reduction, menopause weight gain, or insulin resistance.

At Gaya, this is the conversation I prefer: What is the dominant driver? Is it stubborn weight gain, perimenopause, hormonal imbalance, chronic pain, thyroid disease, insulin resistance, medication weight gain, or sleep collapse? If we do not name the driver, the medication decision becomes guessing in a lab coat.

Risks: Low Dose Does Not Mean No Risk

The first safety question is opioid exposure. Naltrexone blocks opioid receptors. If you take opioid pain medication, use methadone or buprenorphine, recently had surgery, may need opioid pain control, or have undisclosed opioid use, naltrexone can create serious harm. It can block pain relief and may precipitate withdrawal in someone physically dependent on opioids. This is not a side note; it is central to prescribing.

I also want to know about liver disease, heavy alcohol use, pregnancy, breastfeeding, severe nausea history, headaches, insomnia, vivid dreams, mood symptoms, eating disorder history, seizure risk if bupropion is involved, and all current medications. Women are often told that compounded LDN is “low risk.” Sometimes it is well tolerated. But low risk is not the same as no screening.

Compounding adds another layer. Typical LDN doses are often made by compounding pharmacies because commercial tablets do not come in the small doses clinicians commonly use. That makes pharmacy quality, filler selection, dose accuracy, titration, and follow-up important. If you are handed LDN without a clear diagnosis, safety review, medication reconciliation, and stop rule, the plan is too casual.

Women in midlife may also be juggling menopause treatment, perimenopause treatment, sleep medication, antidepressants, pain care, thyroid medication, or hormone replacement therapy. That does not mean LDN is forbidden. It means the prescriber has to practice medicine, not trend management.

Results: What Is Realistic

When a patient asks what results to expect from LDN 8mg, I tell her the truth: weight results are unpredictable. Some patients notice better pain, fewer flares, improved sleep, less alcohol craving, or subtle appetite changes. Some notice nothing. Some stop because of nausea, headaches, sleep disturbance, mood changes, or no measurable benefit. Meaningful fat loss from LDN alone should not be promised.

For obesity treatment, this is a problem. A woman with prediabetes, sleep apnea, fatty liver risk, hypertension, or rapid central weight gain does not need six more months of vague hope. She needs a plan with measurable targets: weight, waist circumference, blood pressure, A1c, lipids, liver enzymes when relevant, sleep quality, protein intake, strength, side effects, and adherence.

The COR-BMOD trial studied naltrexone sustained release plus bupropion sustained release with intensive behavior modification for 56 weeks. That is useful evidence for a combination medication plus structured lifestyle intervention. It should not be translated into “LDN 8mg alone will produce the same result.” Different drugs, different doses, different protocol, different claim.

A reasonable LDN trial, when appropriate, should have a defined purpose and timeline. Are we measuring pain, flares, sleep, cravings, or weight? What change would count as success? What side effects would make us stop? What happens if nothing changes after 8 to 12 weeks? Without those answers, LDN becomes another place for a woman to blame herself when the plan was never strong enough.

When LDN Is the Wrong Centerpiece

LDN should not be the centerpiece when the clinical problem is clear metabolic disease. If a woman has obesity with insulin resistance, prediabetes, hypertension, sleep apnea, high visceral fat, PCOS, fatty liver markers, severe food noise, or repeated regain after structured attempts, I want her evaluated for evidence-based medical weight loss. That may include nutrition, resistance training, sleep treatment, medication review, and anti-obesity medication when appropriate.

For many women, the stronger conversation is medical weight loss, weight loss injections, semaglutide, tirzepatide, or a plan that combines metabolic treatment with hormone evaluation. GLP-1 and dual-incretin medications are not perfect and are not for everyone, but they have stronger obesity evidence than LDN alone.

The menopause piece matters too. I do not prescribe hormones as a weight-loss drug, but I do not ignore hormones when they are driving sleep disruption, central fat gain, mood changes, hot flashes, joint pain, or loss of training capacity. A patient may need Hormonal Agency, Her Longevity, or a weight-loss pathway with hormone oversight. The point is not to collect programs. The point is to match the plan to the physiology.

If LDN is used, it should fit inside that broader plan. Protein targets, fiber, resistance training, alcohol review, sleep evaluation, medication reconciliation, labs, and muscle protection still matter. A medication that does not protect muscle, address appetite biology, or treat insulin resistance cannot carry the whole metabolic plan.

How Gaya Frames the Decision

At Gaya, I begin with the question the medication cannot answer by itself: what problem are we treating? If the answer is “I want weight loss,” that is not specific enough. Are we treating obesity, inflammation, cravings, alcohol use, chronic pain, menopause sleep disruption, insulin resistance, or food noise? Each answer points to a different medical strategy.

Then I ask whether the proposed treatment is strong enough for the risk level. A woman with mild weight gain and chronic pain may reasonably discuss LDN as one piece of care. A woman with rising A1c, central weight gain, hypertension, hot flashes, poor sleep, and a history of failed dieting needs a more comprehensive plan. In that case, Weight Loss Concierge is usually the better starting point because it can address medication strategy, hormone context, labs, nutrition, and follow-up together.

I also care about the emotional cost of weak plans. Women are told to be patient with strategies that were never likely to work. Then, when the scale does not move, they decide their body is broken. That is not informed consent. Informed consent includes evidence strength, expected result range, safety risks, alternatives, cost, and a point at which we stop and choose differently.

LDN 8mg may have a place. It may help the right patient with the right target and the right monitoring. But for weight loss, it should be presented with humility. The evidence does not support calling LDN alone a dependable obesity treatment, and women deserve more than optimistic extrapolation.

If your weight has changed despite effort, the next step is not to chase the newest quiet workaround. The next step is to identify the driver, choose a treatment strong enough for that driver, and measure whether it is working. Evidence where evidence exists. Honesty where it does not.

Dr. Shweta Patel, MD, FACOG

Board-certified OB/GYN, U.S. Navy veteran, and founder of Gaya Wellness. Dr. Patel leads physician-managed programs in medical weight loss, hormone optimization, and longevity medicine for women in midlife and beyond.

You have not failed. Your plan did.